Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma

T. Ohnoshi, K. Hayashi, J. Mizuta, S. Tagawa, S. Matsutomo, Shinya Saito, K. Kawashima, T. Akagi, I. Kimura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In an attempt to assess the effects and toxicity of brief induction chemotherapy plus involved-field irradiation for localized intermediate- and high-grade non-Hodgkin's lymphoma, we conducted a single arm prospective trial between May 1987 and July 1991. Patients received four cycles of a five-drug chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin (CHOP-Bleo) followed by involved-field irradiation of 30 Gy. Of 32 patients consecutively enrolled, 30 patients had measurable and/or evaluable disease, while two had no evaluable disease, as their major tumors had been surgically removed. All the patients were in complete remission at the conclusion of all treatment. Four patients have relapsed so far and one died of the disease at 17 months. With a median follow-up time of 33 months (range, 8 to 58), the actuarial disease-free survival rate was 82% and the overall survival rate was 96%. The toxicity was generally mild and all the patients received the planned treatment course. This treatment modality appeared to be safe and effective for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalInternational Journal of Hematology
Volume57
Issue number1
Publication statusPublished - 1993

Fingerprint

Induction Chemotherapy
Non-Hodgkin's Lymphoma
Therapeutics
Survival Rate
Bleomycin
Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma. / Ohnoshi, T.; Hayashi, K.; Mizuta, J.; Tagawa, S.; Matsutomo, S.; Saito, Shinya; Kawashima, K.; Akagi, T.; Kimura, I.

In: International Journal of Hematology, Vol. 57, No. 1, 1993, p. 61-66.

Research output: Contribution to journalArticle

Ohnoshi, T, Hayashi, K, Mizuta, J, Tagawa, S, Matsutomo, S, Saito, S, Kawashima, K, Akagi, T & Kimura, I 1993, 'Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma', International Journal of Hematology, vol. 57, no. 1, pp. 61-66.
Ohnoshi, T. ; Hayashi, K. ; Mizuta, J. ; Tagawa, S. ; Matsutomo, S. ; Saito, Shinya ; Kawashima, K. ; Akagi, T. ; Kimura, I. / Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma. In: International Journal of Hematology. 1993 ; Vol. 57, No. 1. pp. 61-66.
@article{20e7cc68c37146829eeba0a6faa099cc,
title = "Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma",
abstract = "In an attempt to assess the effects and toxicity of brief induction chemotherapy plus involved-field irradiation for localized intermediate- and high-grade non-Hodgkin's lymphoma, we conducted a single arm prospective trial between May 1987 and July 1991. Patients received four cycles of a five-drug chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin (CHOP-Bleo) followed by involved-field irradiation of 30 Gy. Of 32 patients consecutively enrolled, 30 patients had measurable and/or evaluable disease, while two had no evaluable disease, as their major tumors had been surgically removed. All the patients were in complete remission at the conclusion of all treatment. Four patients have relapsed so far and one died of the disease at 17 months. With a median follow-up time of 33 months (range, 8 to 58), the actuarial disease-free survival rate was 82{\%} and the overall survival rate was 96{\%}. The toxicity was generally mild and all the patients received the planned treatment course. This treatment modality appeared to be safe and effective for localized intermediate- and high-grade non-Hodgkin's lymphoma.",
author = "T. Ohnoshi and K. Hayashi and J. Mizuta and S. Tagawa and S. Matsutomo and Shinya Saito and K. Kawashima and T. Akagi and I. Kimura",
year = "1993",
language = "English",
volume = "57",
pages = "61--66",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma

AU - Ohnoshi, T.

AU - Hayashi, K.

AU - Mizuta, J.

AU - Tagawa, S.

AU - Matsutomo, S.

AU - Saito, Shinya

AU - Kawashima, K.

AU - Akagi, T.

AU - Kimura, I.

PY - 1993

Y1 - 1993

N2 - In an attempt to assess the effects and toxicity of brief induction chemotherapy plus involved-field irradiation for localized intermediate- and high-grade non-Hodgkin's lymphoma, we conducted a single arm prospective trial between May 1987 and July 1991. Patients received four cycles of a five-drug chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin (CHOP-Bleo) followed by involved-field irradiation of 30 Gy. Of 32 patients consecutively enrolled, 30 patients had measurable and/or evaluable disease, while two had no evaluable disease, as their major tumors had been surgically removed. All the patients were in complete remission at the conclusion of all treatment. Four patients have relapsed so far and one died of the disease at 17 months. With a median follow-up time of 33 months (range, 8 to 58), the actuarial disease-free survival rate was 82% and the overall survival rate was 96%. The toxicity was generally mild and all the patients received the planned treatment course. This treatment modality appeared to be safe and effective for localized intermediate- and high-grade non-Hodgkin's lymphoma.

AB - In an attempt to assess the effects and toxicity of brief induction chemotherapy plus involved-field irradiation for localized intermediate- and high-grade non-Hodgkin's lymphoma, we conducted a single arm prospective trial between May 1987 and July 1991. Patients received four cycles of a five-drug chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin (CHOP-Bleo) followed by involved-field irradiation of 30 Gy. Of 32 patients consecutively enrolled, 30 patients had measurable and/or evaluable disease, while two had no evaluable disease, as their major tumors had been surgically removed. All the patients were in complete remission at the conclusion of all treatment. Four patients have relapsed so far and one died of the disease at 17 months. With a median follow-up time of 33 months (range, 8 to 58), the actuarial disease-free survival rate was 82% and the overall survival rate was 96%. The toxicity was generally mild and all the patients received the planned treatment course. This treatment modality appeared to be safe and effective for localized intermediate- and high-grade non-Hodgkin's lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0027474425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027474425&partnerID=8YFLogxK

M3 - Article

C2 - 7682860

AN - SCOPUS:0027474425

VL - 57

SP - 61

EP - 66

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -